Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

SIMPLE SUMMARY: Mutations of the BRAF oncogene are reported in tumors of patients with non-small-cell lung cancer in 2–4% of cases (about half of them are V600E mutation). Dabrafenib plus trametinib combination is approved in Europe for BRAF V600E-mutant metastatic non-small-cell lung cancer. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761573/
https://www.ncbi.nlm.nih.gov/pubmed/33276639
http://dx.doi.org/10.3390/cancers12123608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761573/
https://www.ncbi.nlm.nih.gov/pubmed/33276639
http://dx.doi.org/10.3390/cancers12123608

Ejemplares similares